Clincosm LogoSign in Get a demo

RELIEF Europe Study

Sponsor
Torax Medical Incorporated (Industry)
Overall Status
Terminated
CT.gov ID
NCT02762487
Collaborator
(none)
7
Enrollment
4
Locations
1
Arm
15
Duration (Months)
1.8
Patients Per Site
0.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the LINX device in patients who have previously undergone laparoscopic sleeve gastrectomy (LSG) for obesity and have chronic gastroesophageal reflux disease (GERD). The study will monitor safety and changes in reflux symptoms.

Condition or Disease Intervention/Treatment Phase
  • Device: The LINX® Reflux Management System
 N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
7 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
RELIEF Europe Study. A Prospective, Multicenter Study of RefluxManagement With the LINX® System for Gastroesophageal Reflux Disease After Laparoscopic Sleeve Gastrectomy
Study Start Date :
Nov 1, 2015
Actual Primary Completion Date :
Feb 1, 2017
Actual Study Completion Date :
Feb 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: LINX arm

Previous LSG patient will be treated with the LINX device and serve as their own control

Device: The LINX® Reflux Management System
The LINX device is a permanent implant placed at the area of the lower esophageal sphincter (LES) and is designed to augment a weak LES and minimize or eliminate GERD-related symptoms.
Other Names:
  • LINX device

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Change is GERD-HRQL Score as a measure of efficacy [Baseline, 6 month visit]

    2. Number of participants with serious complications as a measure of safety. [6 month visit]

    3. Change is total distal acid exposure as a measure of efficacy. [Baseline, 6 month visit]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    21 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Laparoscopic sleeve gastrectomy (LSG) for obesity >12 months prior to proposed device implantation date.

    • Patient is a surgical candidate, i.e. is able to undergo general anesthesia and laparoscopic surgery.

    • Documented pathologic esophageal acid exposure by pH monitoring per institution's standard of care (i.e. total distal ambulatory esophageal pH< 4 for ≥ 5.3% (BRAVO) or ≥4.5% (transnasal) or abnormal DeMeester Score (>14.72) within 12 months of proposed implantation date (After Sleeve Gastrectomy).

    NOTE: SUBJECTS SHALL HAVE DISCONTINUED ALL GERD MEDICATIONS FOR AT LEAST 7 DAYS PRIOR TO TESTING WITH THE EXCEPTION OF ANTACIDS, WHICH MAY BE TAKEN UP UNTIL THE MORNING OF THE VISIT.

    • Chronic GERD symptoms despite maximum medical therapy for the treatment of reflux.

    • Age ≥ 21 years

    • At least 30% loss of excess weight from date of original LSG surgery.

    • Patient is willing and able to cooperate with follow-up examinations.

    • Patient has been informed of the study procedures and the treatment and has signed an informed consent form.

    Exclusion Criteria:

    • Suspected or known allergies to titanium, stainless steel, nickel, or ferrous materials.

    • Prior surgery in the area of the gastroesophageal junction (GEJ), including prior hiatal hernia repair.

    • Presence of ˃3 cm hiatal hernia as determined by endoscopy or barium esophagram.

    • Subject had any major complications related to the laparoscopic sleeve gastrectomy that may interfere with, or increase the risks of the LINX procedure (such as, but not limited to, leaks from the gastric remnant and infection at the sleeve gastrectomy).

    • Plans to surgically revise the gastric pouch (either known preoperatively or decided intraoperatively).

    • Currently being treated with another investigational drug or investigational device.

    • Suspected or confirmed esophageal or gastric cancer or prior gastric or esophageal surgery or endoscopic intervention for GERD (with the exception of sleeve gastrectomy).

    • Distal amplitude <35 mmHg or <70% peristaltic sequences.

    • Presence of esophagitis - Grade C or D (LA Classification). BMI >35.

    • Symptoms of dysphagia more than once per week within the last 3 months.

    • Diagnosed with Scleroderma.

    • Diagnosed with an esophageal motility disorder such as but not limited to achalasia, nutcracker esophagus, or diffuse esophageal spasm or hypertensive LES.

    • Patient has a history of or known esophageal stricture or gross esophageal anatomic abnormalities (Schatzki's ring, obstructive lesions, etc.).

    • Patient has esophageal or gastric varices.

    • Patient has Barrett's esophagus.

    • Patient cannot understand trial requirements or is unable to comply with follow-up schedule.

    • Pregnant or nursing, or plans to become pregnant during the course of the study.

    • Any reason which the Investigator believes may cause the subject to be non-compliant with or unable to meet the protocol requirements.

    • Patient has an electrical implant or metallic, abdominal implants.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Schön Klinik Nürnberg Fürth Germany 90763
    2 EvK Herne Herne Germany 44623
    3 Uni Klinik Leipzig Leipzig Germany
    4 Policlinico San Donato Milan Italy 20097

    Sponsors and Collaborators

    • Torax Medical Incorporated

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Torax Medical Incorporated
    ClinicalTrials.gov Identifier:
    NCT02762487
    Other Study ID Numbers:
    • 4700
    First Posted:
    May 5, 2016
    Last Update Posted:
    Oct 16, 2017
    Last Verified:
    Oct 1, 2017
    Additional relevant MeSH terms:
    Gastroesophageal Reflux

    Study Results

    No Results Posted as of Oct 16, 2017